Danaher Announces Conversion Date For Series A Mandatory Convertible Preferred Stock

Danaher Announces Conversion Date For Series A Mandatory Convertible Preferred Stock WASHINGTON, April 12, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that its 4.75% Series A Mandatory Convertible Preferred Stock (the “Preferred Stock”), will automatically convert into shares of the Company’s Common Stock on April 15, 2022 (the “Conversion Date”). The conversion rate... Read more

Bruker Announces Key Innovations for Multiplexed Spatial Proteomics and Unbiased Multiomic Imaging for Cancer Research

Bruker launches novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF fleX using AmberGen’s HiPLEX-IHC peptide code antibody probes, combined with unbiased lipidomics, glycomics and metabolomics tissue imaging New Canopy CellScape™ single cell, highly quantitative spatial proteomic ChipCytometry™ platform features fully automated iterative staining using open-source antibodies for virtually unlimited immuno-oncology marker analysis on whole tissue... Read more

Thermo Fisher Scientific to Host Investor Day

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2022 Investor Day on Wednesday, May 18, starting at 9:00 a.m. (ET), at the Mandarin Oriental New York, 80 Columbus Circle at 60th Street, in New York City. The format will feature presentations by... Read more

PerkinElmer Showcases Expanded Technology and Solutions Portfolio to Accelerate Cancer Research at AACR Annual Meeting

Innovative solutions offer researchers flexible therapeutic tools to deepen understanding of cancer’s biology to enable advances in immunotherapy, targeted treatments, and personalized medicine WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, will be at The American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans (booths... Read more

PerkinElmer Expands In Vivo Instruments Portfolio with Hands-free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System

Launches first-of-its-kind automated ultrasound platform to accelerate preclinical research WALTHAM, Mass.–(BUSINESS WIRE)–Apr. 7, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the expansion of its in vivo imaging portfolio with the launch of the Vega® imaging system, a first-of-its kind ultrasound platform that combines hands-free, automated... Read more